MacroGenics Holds Annual Stockholders Meeting on May 21

The latest update is out from MacroGenics ( (MGNX) ).

On May 21, 2025, MacroGenics, Inc. held its Annual Meeting of Stockholders, where approximately 82% of the company’s common stock was represented. During the meeting, stockholders elected four Class III directors for a three-year term, ratified the appointment of Ernst & Young LLP as the independent auditor for 2025, approved executive compensation, and amended the 2023 Equity Incentive Plan to increase available shares by 1,250,000. These decisions reflect the company’s ongoing governance and strategic planning efforts, potentially impacting its operational focus and shareholder value.

The most recent analyst rating on (MGNX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.

Spark’s Take on MGNX Stock

According to Spark, TipRanks’ AI Analyst, MGNX is a Neutral.

MacroGenics demonstrates a mix of strengths and weaknesses. Significant revenue growth and clinical progress are offset by persistent profitability issues and increased operational costs. The technical indicators suggest bearish trends, and valuation metrics are not favorable. Despite these challenges, the company’s strong cash position offers some financial stability and potential for future growth.

To see Spark’s full report on MGNX stock, click here.

More about MacroGenics

MacroGenics, Inc. operates in the biotechnology industry, focusing on the development of monoclonal antibody-based therapeutics for the treatment of cancer. The company is engaged in the research and development of innovative medicines that target cancer and other serious diseases, aiming to improve patient outcomes.

Average Trading Volume: 690,109

Technical Sentiment Signal: Sell

Current Market Cap: $99.05M

Learn more about MGNX stock on TipRanks’ Stock Analysis page.